Medicines Supply Continuity – Update on No Deal EU Exit Contingency Plans
The Chief Pharmaceutical Officer for England has written to pharmacists working in and with the NHS in England to update them on Government contingency plans for continuity of medicines supply in the event of a No Deal Exit from the EU. The letter reiterates advice about the additional pressure on medicines supplies that stockpiling can cause and provides information Continue Reading »
Getting Medication – Government Statement
The Department of Health & Social Care have published a policy paper on access to medicines in the UK – including information about contingency plans for a ‘No Deal Brexit’. DHSC 18/01/2019 The government is working with pharmaceutical companies, suppliers, and the NHS to make sure patients continue to receive the medication they need if the UK leaves Continue Reading »
UKMi Q&A via SPS – New Resources
UKMi publish a series of Q&A documents on the NHS SPS website, with summaries of high quality, evidence-based, and quality controlled answers to common or unusual Medicines Information enquiries. The latest batch of seven new or updated Q&As was published in December: Which medicines require extra care when switching between liquid and tablet/capsule formulations? Information on medicines which require Continue Reading »
SPS Resources – UKMi Q&A documents
The UK Medicines Infomation network publish a series of Question & Answer documents via the NHS Specialist Pharmacy Service website. The Q&As are a response to demand for accessible summaries of high quality, evidence-based, and quality controlled answers to common or unusual enquiries made to Medicines Information services. A full list of current UKMi Q&As can be found here, Continue Reading »
Aldosterone Antagonist Monitoring: Room for Improvement in UK Primary Care
NICE recommend offering or considering the addition of an aldosterone antagonist (AA), such as spironolactone and eplerenone, to treatment with an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker (ACEI/ARB) for management of treatment-resistant heart failure or hypertension and for patients who have had an acute MI and who have symptoms and/or signs of heart failure and left ventricular systolic dysfunction. Continue Reading »